|Bid||1.8000 x 1800|
|Ask||1.9300 x 900|
|Day's Range||1.8600 - 2.0000|
|52 Week Range||1.8600 - 5.3900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Acer Therapeutics Inc. ( NASDAQ:ACER ) is possibly approaching a major achievement in its business, so we would like to...
The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up.
Opexa Therapeutics, Inc. (ACER) delivered earnings and revenue surprises of 36.11% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?